U-Blot® Research Grade Obiltoxaximab

Name: U-Blot® Research Grade Obiltoxaximab
SKU: WA3252
Availability: InStock

$9,999.00

Size:50ug

SKU: WA3252-50

Catalog No.: WA3252

Specification: 50ug/100ug

Stock: In stock

Product details, specifications, documents, and related products are available from the catalog record. Learn more

Product details Specifications Q & A Education

Product details, specifications, documents, and related products are available from the catalog record.

Product Overview

Catalog No.: WA3252
SKU: WA3252-50
Category: Biosimilar Antibodies
Product Type: Other
Size: 50ug/100ug
Stock Status: In stock
Available Stock: 999
Minimum Order Quantity: 1

Storage & Compliance

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Research Use Only: Yes

Additional Specifications

PackSize: 50ug/100ug
Target: Protective antigen
Reactivity: Bacillus anthracis
Applications: ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host Species: Chimeric
Isotype: IgG1-kappa
Conjugate/Modification: --
Recommended Dilution Ratio: --
Composition: 0.01M PBS, pH 7.4.
Purification Process: Protein A/G purified from cell culture supernatant.
Purity: >95% purity as determined by SDS-PAGE.
storageCondition: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Clonality: Monoclonal
Clone Number: --
Immunogen: Mammalian Cells
Alias: Protective antigen, PA, Anthrax toxins translocating protein, PA-83, PA83, Protective antigen PA-20, PA-20, PA20, Protective antigen PA-63, PA-63, PA63, pagA, pag, pXO1-110, BXA0164, GBAA_pXO1_0164
Species: --
Gene ID-1: P13423
Uniprot: --
Background: Obiltoxaximab (ETI-204, trade name Anthim) is an affinity-enhanced, chimeric IgG1 kappa monoclonal antibody (mAb) developed by Elusys Therapeutics and the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) for the prevention and treatment of inhalational anthrax due to Bacillus anthracis. Obiltoxaximab binds the protective antigen (PA) component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa. Obiltoxaximab has been designed to neutralize the free protective antigen of B. anthracis, thereby inhibiting the lethal effects of anthrax toxins. In March 2016, intravenous obiltoxaximab was approved in the USA for the treatment (in combination with appropriate antibacterial drugs) and prophylaxis of inhalational anthrax.<br>
Tissue Expression: --
Signaling_pathway: --
Research Areas: --

Tech Support

ucallm

Documents

Datasheet, COA, SDS, and protocol files can be requested from technical support.

Storage & Handling

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.